Drug Proscar is shown to reduce need for prostate surgery, study reveals

March 1998
Jet;03/23/98, Vol. 93 Issue 17, p24
Reports on research indicating that the drug Proscar can reduce the need for surgery to treat enlarged prostate glands. Details of the four-year study conducted by John D. McConnell and colleagues and published in the `New England Journal of Medicine.'


Related Articles

  • Cost effectiveness of finasteride: a risky business?  // PharmacoEconomics & Outcomes News;7/10/2010, Issue 607, p6 

    The article discusses the cost effectiveness of finasteride chemoprevention for treating prostate cancer, referencing a study by S. Reed and colleagues presented at the 105th Annual Meeting of the American Urological Association.

  • Detection Bias Due to the Effect of Finasteride on Prostate Volume: A Modeling Approach for Analysis of the Prostate Cancer Prevention Trial. Cohen, Yael C.; Liu, Kenneth S.; Heyden, Norman L.; Carides, Alexandra D.; Anderson, Keaven M.; Daifotis, Anastasia G.; Gann, Peter H. // JNCI: Journal of the National Cancer Institute;9/19/2007, Vol. 99 Issue 18, p1366 

    Background The Prostate Cancer Prevention Trial (PCPT) demonstrated a 24.8% reduction in the 7-year prevalence of prostate cancer among patients treated with finasteride (5 mg daily) compared with that among patients treated with placebo; however, a 25.5% increase in the prevalence of...

  • Finasteride and High-Grade Prostate Cancer in the Prostate Cancer Prevention Trial. Lucia, M. Scott; Epstein, Jonathan I.; Goodman, Phyllis J.; Darke, Amy K.; Reuter, Victor E.; Civantos, Francisco; Tangen, Catherine M.; Parnes, Howard L.; Lippman, Scott M.; La Rosa, Francisco G.; Kattan, Michael W.; Crawford, E. David; Ford, Leslie G.; Coltman Jr., Charles A.; Thompson, Ian M. // JNCI: Journal of the National Cancer Institute;9/19/2007, Vol. 99 Issue 18, p1375 

    Background The Prostate Cancer Prevention Trial (PCPT) reported a decreased incidence of prostate cancer overall but an increase in the incidence of high-grade prostate cancer with finasteride compared with placebo. We assessed whether the increased high-grade prostate cancer associated with...

  • Finasteride not cost effective for prostate cancer prophylaxis.  // PharmacoEconomics & Outcomes News;11/5/2005, Issue 490, p11 

    The article discusses a study which suggested that prostate cancer chemoprophylaxis with finasteride is not cost effective in the U.S. They constructed a decision-analysis Markov model to estimate the lifetime costs and outcomes associated with finasteride 5 mg/day or no such primary prevention...

  • Diagnostic evaluation of PSA recurrence and review of hormonal management after radical prostatectomy. Van Poppel, H.; Joniau, S.; Van Cleynenbreugel, B.; Mottaghy, F. M.; Oyen, R. // Prostate Cancer & Prostatic Diseases;2009, Vol. 12 Issue 2, p116 

    The aim of this review is to provide a discussion of the diagnostic evaluation of biochemical recurrence following radical prostatectomy (RP) and an overview of the postoperative hormonal treatment (HT) options. As no randomized trials in the clinical setting of postoperative prostate-specific...

  • Abstracts.  // Geriatrics;Sep2003, Vol. 58 Issue 9, p44 

    Presents abstracts of research in geriatric care. Effect of mentally-demanding activities on decreasing the risk of dementia; Use of finasteride to reduce the risk of prostate cancer; Risk of death and vascular incidence among patients with rheumatoid arthritis.

  • Chemoprevention of Prostate Cancer. Walsh, Patrick C. // New England Journal of Medicine;4/1/2010, Vol. 362 Issue 13, p1237 

    The author discusses issues related to the chemoprevention of prostate cancer, which is one of the most common types of cancer among men in the U.S. He says that the use of drugs like finasteride and dutasteride for prevention is quite risky because they shrink tumors temporarily but they do not...

  • The Prevention of Prostate Cancer – The Dilemma Continues. Scardino, Peter T. // New England Journal of Medicine;7/17/2003, Vol. 349 Issue 3, p297 

    The author assesses the therapeutic use of finasteride to prevent prostate cancer among men in the U.S. The drug, approved by the U.S. Food and Drug Administration as an oral medication for the treatment of symptoms of benign prostatic hyperplasia, inhibits the conversion of testosterone to...

  • Transparency and reproducibility in data analysis: the Prostate Cancer Prevention Trial. Baker, Stuart G.; Darke, Amy K.; Pinsky, Paul; Parnes, Howard L.; Kramer, Barnett S. // Biostatistics;Jul2010, Vol. 11 Issue 3, p413 

    With the analysis of complex, messy data sets, the statistics community has recently focused attention on “reproducible research,” namely research that can be readily replicated by others. One standard that has been proposed is the availability of data sets and computer code....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics